Which has preferable valuation and earnings, LPCN or CLNN?

Lipocine has higher revenue and earnings than Clene. Clene is trading at a lower price-to-earnings ratio than Lipocine, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Lipocine $1.98M 10.36 -$9.63M -$1.88 N/A Clene $200K 405.13 -$26.17M -$3.20 N/A

Is LPCN or CLNN more profitable?

Lipocine has a net margin of -571.18% compared to Clene's net margin of -25,009.70%. Clene's return on equity of 0.00% beat Lipocine's return on equity. Company Net Margins Return on Equity Return on Assets Lipocine -571.18% -66.70% -59.39% Clene -25,009.70% N/A -137.98%

Is LPCN or FRMM more profitable?

Forum Markets has a net margin of 0.00% compared to Lipocine's net margin of -571.18%. Lipocine's return on equity of -66.70% beat Forum Markets' return on equity. Company Net Margins Return on Equity Return on Assets Lipocine -571.18% -66.70% -59.39% Forum Markets N/A -242.09% -135.46%

Does the media prefer LPCN or FRMM?

In the previous week, Lipocine had 1 more articles in the media than Forum Markets. MarketBeat recorded 3 mentions for Lipocine and 2 mentions for Forum Markets. Forum Markets' average media sentiment score of 0.77 beat Lipocine's score of 0.39 indicating that Forum Markets is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Lipocine 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Forum Markets 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger earnings & valuation, ENTX or LPCN?

Lipocine has higher revenue and earnings than Entera Bio. Entera Bio is trading at a lower price-to-earnings ratio than Lipocine, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Entera Bio $40K 2,033.21 -$11.44M -$0.27 N/A Lipocine $1.98M 10.36 -$9.63M -$1.88 N/A

Is ENTX or LPCN more profitable?

Entera Bio has a net margin of 0.00% compared to Lipocine's net margin of -571.18%. Lipocine's return on equity of -66.70% beat Entera Bio's return on equity. Company Net Margins Return on Equity Return on Assets Entera Bio N/A -83.31% -70.83% Lipocine -571.18% -66.70% -59.39%

Does the media refer more to ENTX or LPCN?

In the previous week, Lipocine had 1 more articles in the media than Entera Bio. MarketBeat recorded 3 mentions for Lipocine and 2 mentions for Entera Bio. Entera Bio's average media sentiment score of 0.72 beat Lipocine's score of 0.39 indicating that Entera Bio is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Entera Bio 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Lipocine 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor PLRX or LPCN?

In the previous week, Lipocine had 1 more articles in the media than Pliant Therapeutics. MarketBeat recorded 3 mentions for Lipocine and 2 mentions for Pliant Therapeutics. Pliant Therapeutics' average media sentiment score of 0.94 beat Lipocine's score of 0.39 indicating that Pliant Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Pliant Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Lipocine 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend LPCN or XBIT?

Lipocine presently has a consensus target price of $15.00, indicating a potential upside of 502.41%. Given Lipocine's stronger consensus rating and higher probable upside, research analysts plainly believe Lipocine is more favorable than XBiotech. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Lipocine 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.33 XBiotech 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better earnings & valuation, LPCN or XBIT?

Lipocine has higher revenue and earnings than XBiotech. XBiotech is trading at a lower price-to-earnings ratio than Lipocine, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Lipocine $1.98M 10.36 -$9.63M -$1.88 N/A XBiotech N/A N/A -$45.54M -$1.32 N/A

Is LPCN or XBIT more profitable?

XBiotech has a net margin of 0.00% compared to Lipocine's net margin of -571.18%. XBiotech's return on equity of -26.10% beat Lipocine's return on equity. Company Net Margins Return on Equity Return on Assets Lipocine -571.18% -66.70% -59.39% XBiotech N/A -26.10% -25.06%

Lipocine (LPCN) Competitors

$2.49 +0.03 (+1.22%)

Closing price 04:00 PM Eastern

Extended Trading

$2.49 +0.00 (+0.04%)

As of 05:23 PM Eastern

Compare

LPCN vs. CLNN, FRMM, ENTX, PLRX, and XBIT

Should you buy Lipocine stock or one of its competitors? MarketBeat compares Lipocine with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Lipocine include Clene (CLNN), Forum Markets (FRMM), Entera Bio (ENTX), Pliant Therapeutics (PLRX), and XBiotech (XBIT). These companies are all part of the "pharmaceutical products" industry.

How does Lipocine compare to Clene?

Lipocine (NASDAQ:LPCN) and Clene (NASDAQ:CLNN) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, risk, analyst recommendations, dividends, earnings, profitability, valuation and institutional ownership.

9.1% of Lipocine shares are owned by institutional investors. Comparatively, 23.3% of Clene shares are owned by institutional investors. 6.4% of Lipocine shares are owned by company insiders. Comparatively, 28.3% of Clene shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Lipocine currently has a consensus target price of $15.00, indicating a potential upside of 502.41%. Clene has a consensus target price of $33.25, indicating a potential upside of 424.45%. Given Lipocine's higher possible upside, equities research analysts clearly believe Lipocine is more favorable than Clene.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lipocine	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.33
Clene	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

Lipocine has a net margin of -571.18% compared to Clene's net margin of -25,009.70%. Clene's return on equity of 0.00% beat Lipocine's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lipocine	-571.18%	-66.70%	-59.39%
Clene	-25,009.70%	N/A	-137.98%

Lipocine has a beta of 0.48, suggesting that its share price is 52% less volatile than the broader market. Comparatively, Clene has a beta of 0.91, suggesting that its share price is 9% less volatile than the broader market.

In the previous week, Lipocine had 2 more articles in the media than Clene. MarketBeat recorded 3 mentions for Lipocine and 1 mentions for Clene. Clene's average media sentiment score of 0.94 beat Lipocine's score of 0.39 indicating that Clene is being referred to more favorably in the news media.

Company	Overall Sentiment
Lipocine	Neutral
Clene	Positive

Lipocine has higher revenue and earnings than Clene. Clene is trading at a lower price-to-earnings ratio than Lipocine, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lipocine	$1.98M	10.36	-$9.63M	-$1.88	N/A
Clene	$200K	405.13	-$26.17M	-$3.20	N/A

Summary

Lipocine beats Clene on 9 of the 17 factors compared between the two stocks.

How does Lipocine compare to Forum Markets?

Lipocine (NASDAQ:LPCN) and Forum Markets (NASDAQ:FRMM) are both small-cap pharmaceutical products companies, but which is the better business? We will contrast the two companies based on the strength of their valuation, risk, dividends, analyst recommendations, profitability, institutional ownership, media sentiment and earnings.

Lipocine currently has a consensus target price of $15.00, indicating a potential upside of 502.41%. Forum Markets has a consensus target price of $10.00, indicating a potential upside of 73.01%. Given Lipocine's higher possible upside, analysts clearly believe Lipocine is more favorable than Forum Markets.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lipocine	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.33
Forum Markets	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50

Forum Markets has a net margin of 0.00% compared to Lipocine's net margin of -571.18%. Lipocine's return on equity of -66.70% beat Forum Markets' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lipocine	-571.18%	-66.70%	-59.39%
Forum Markets	N/A	-242.09%	-135.46%

9.1% of Lipocine shares are held by institutional investors. Comparatively, 4.1% of Forum Markets shares are held by institutional investors. 6.4% of Lipocine shares are held by insiders. Comparatively, 15.1% of Forum Markets shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Lipocine has higher earnings, but lower revenue than Forum Markets. Lipocine is trading at a lower price-to-earnings ratio than Forum Markets, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lipocine	$1.98M	10.36	-$9.63M	-$1.88	N/A
Forum Markets	$6.55M	12.83	-$450.52M	-$36.07	N/A

In the previous week, Lipocine had 1 more articles in the media than Forum Markets. MarketBeat recorded 3 mentions for Lipocine and 2 mentions for Forum Markets. Forum Markets' average media sentiment score of 0.77 beat Lipocine's score of 0.39 indicating that Forum Markets is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lipocine	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Forum Markets	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Lipocine has a beta of 0.48, suggesting that its stock price is 52% less volatile than the broader market. Comparatively, Forum Markets has a beta of 1.45, suggesting that its stock price is 45% more volatile than the broader market.

Summary

Forum Markets beats Lipocine on 9 of the 16 factors compared between the two stocks.

How does Lipocine compare to Entera Bio?

Entera Bio (NASDAQ:ENTX) and Lipocine (NASDAQ:LPCN) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, institutional ownership, media sentiment, valuation, earnings, dividends, analyst recommendations and risk.

Entera Bio currently has a consensus target price of $9.00, suggesting a potential upside of 445.45%. Lipocine has a consensus target price of $15.00, suggesting a potential upside of 502.41%. Given Lipocine's stronger consensus rating and higher possible upside, analysts clearly believe Lipocine is more favorable than Entera Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Entera Bio	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Lipocine	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.33

In the previous week, Lipocine had 1 more articles in the media than Entera Bio. MarketBeat recorded 3 mentions for Lipocine and 2 mentions for Entera Bio. Entera Bio's average media sentiment score of 0.72 beat Lipocine's score of 0.39 indicating that Entera Bio is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Entera Bio	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Lipocine	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

14.1% of Entera Bio shares are owned by institutional investors. Comparatively, 9.1% of Lipocine shares are owned by institutional investors. 10.6% of Entera Bio shares are owned by insiders. Comparatively, 6.4% of Lipocine shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Lipocine has higher revenue and earnings than Entera Bio. Entera Bio is trading at a lower price-to-earnings ratio than Lipocine, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Entera Bio	$40K	2,033.21	-$11.44M	-$0.27	N/A
Lipocine	$1.98M	10.36	-$9.63M	-$1.88	N/A

Entera Bio has a beta of 1.56, indicating that its stock price is 56% more volatile than the broader market. Comparatively, Lipocine has a beta of 0.48, indicating that its stock price is 52% less volatile than the broader market.

Entera Bio has a net margin of 0.00% compared to Lipocine's net margin of -571.18%. Lipocine's return on equity of -66.70% beat Entera Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Entera Bio	N/A	-83.31%	-70.83%
Lipocine	-571.18%	-66.70%	-59.39%

Summary

Lipocine beats Entera Bio on 9 of the 17 factors compared between the two stocks.

How does Lipocine compare to Pliant Therapeutics?

Pliant Therapeutics (NASDAQ:PLRX) and Lipocine (NASDAQ:LPCN) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, media sentiment, dividends, profitability, earnings, analyst recommendations, risk and valuation.

In the previous week, Lipocine had 1 more articles in the media than Pliant Therapeutics. MarketBeat recorded 3 mentions for Lipocine and 2 mentions for Pliant Therapeutics. Pliant Therapeutics' average media sentiment score of 0.94 beat Lipocine's score of 0.39 indicating that Pliant Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Pliant Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Lipocine	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

97.3% of Pliant Therapeutics shares are held by institutional investors. Comparatively, 9.1% of Lipocine shares are held by institutional investors. 6.4% of Pliant Therapeutics shares are held by insiders. Comparatively, 6.4% of Lipocine shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Pliant Therapeutics has a net margin of 0.00% compared to Lipocine's net margin of -571.18%. Pliant Therapeutics' return on equity of -58.11% beat Lipocine's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pliant Therapeutics	N/A	-58.11%	-44.37%
Lipocine	-571.18%	-66.70%	-59.39%

Pliant Therapeutics has a beta of 1.2, suggesting that its stock price is 20% more volatile than the broader market. Comparatively, Lipocine has a beta of 0.48, suggesting that its stock price is 52% less volatile than the broader market.

Pliant Therapeutics presently has a consensus target price of $3.00, suggesting a potential upside of 160.87%. Lipocine has a consensus target price of $15.00, suggesting a potential upside of 502.41%. Given Lipocine's stronger consensus rating and higher possible upside, analysts clearly believe Lipocine is more favorable than Pliant Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pliant Therapeutics	2 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.80
Lipocine	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.33

Lipocine has higher revenue and earnings than Pliant Therapeutics. Lipocine is trading at a lower price-to-earnings ratio than Pliant Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pliant Therapeutics	N/A	N/A	-$149.34M	-$1.84	N/A
Lipocine	$1.98M	10.36	-$9.63M	-$1.88	N/A

Summary

Pliant Therapeutics beats Lipocine on 10 of the 16 factors compared between the two stocks.

How does Lipocine compare to XBiotech?

Lipocine (NASDAQ:LPCN) and XBiotech (NASDAQ:XBIT) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, risk, profitability, media sentiment, dividends, valuation and earnings.

Lipocine has a beta of 0.48, meaning that its share price is 52% less volatile than the broader market. Comparatively, XBiotech has a beta of 0.85, meaning that its share price is 15% less volatile than the broader market.

XBiotech has a net margin of 0.00% compared to Lipocine's net margin of -571.18%. XBiotech's return on equity of -26.10% beat Lipocine's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lipocine	-571.18%	-66.70%	-59.39%
XBiotech	N/A	-26.10%	-25.06%

In the previous week, Lipocine had 2 more articles in the media than XBiotech. MarketBeat recorded 3 mentions for Lipocine and 1 mentions for XBiotech. XBiotech's average media sentiment score of 1.87 beat Lipocine's score of 0.39 indicating that XBiotech is being referred to more favorably in the news media.

Company	Overall Sentiment
Lipocine	Neutral
XBiotech	Very Positive

9.1% of Lipocine shares are owned by institutional investors. Comparatively, 55.7% of XBiotech shares are owned by institutional investors. 6.4% of Lipocine shares are owned by company insiders. Comparatively, 30.8% of XBiotech shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Lipocine presently has a consensus target price of $15.00, indicating a potential upside of 502.41%. Given Lipocine's stronger consensus rating and higher probable upside, research analysts plainly believe Lipocine is more favorable than XBiotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lipocine	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.33
XBiotech	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Lipocine has higher revenue and earnings than XBiotech. XBiotech is trading at a lower price-to-earnings ratio than Lipocine, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lipocine	$1.98M	10.36	-$9.63M	-$1.88	N/A
XBiotech	N/A	N/A	-$45.54M	-$1.32	N/A

Summary

XBiotech beats Lipocine on 8 of the 15 factors compared between the two stocks.

Get Lipocine News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding LPCN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

LPCN vs. The Competition

Export

Metric	Lipocine	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$20.28M	$3.04B	$6.85B	$12.20B
Dividend Yield	N/A	1.87%	2.66%	6.22%
P/E Ratio	-1.33	19.67	26.04	24.36
Price / Sales	10.36	349.52	550.39	103.01
Price / Cash	N/A	56.85	29.09	36.93
Price / Book	0.95	4.25	10.98	6.49
Net Income	-$9.63M	$64.45M	$3.57B	$336.61M
7 Day Performance	8.73%	4.17%	3.06%	0.90%
1 Month Performance	10.67%	1.44%	0.72%	-0.36%
1 Year Performance	-24.32%	34.07%	36.82%	31.26%

Lipocine Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
LPCN Lipocine	3.8474 of 5 stars	$2.49 +1.2%	$15.00 +502.4%	-25.2%	$20.28M	$1.98M	N/A	10
CLNN Clene	3.3553 of 5 stars	$5.77 -2.0%	$33.25 +476.3%	+61.2%	$75.26M	$200K	N/A	100	Analyst Downgrade
FRMM Forum Markets	2.3712 of 5 stars	$5.03 -2.5%	$10.00 +98.8%	N/A	$75.04M	$6.55M	N/A	7	Analyst Downgrade Gap Down
ENTX Entera Bio	2.5159 of 5 stars	$1.55 +4.7%	$9.00 +480.6%	-13.1%	$72.95M	$40K	N/A	20	Gap Up
PLRX Pliant Therapeutics	2.6823 of 5 stars	$1.16 flat	$3.00 +158.6%	-8.8%	$71.83M	$1.58M	N/A	90	News Coverage

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:LPCN) was last updated on 6/29/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Lipocine (LPCN) Competitors